Immunomedics Begins Patient Dosing in Veltuzumab Phase I/II Trial
Posted on: Wednesday, 6 February 2008, 03:00 CST
Immunomedics has announced that patient dosing has begun in a Phase I/II clinical trial evaluating the safety, tolerability and early indication of efficacy of veltuzumab, its humanized anti-CD20 monoclonal antibody, for the treatment of immune thrombocytopenic purpura.
The company said that the first patient enrolled in this study responded very favorably to veltuzumab. Prior to receiving a single dose of 80mg of veltuzumab, the patient had a platelet count of less than 30 x 10(9)/L (normal range is above 150 x 10(9)/L). Two days post-therapy, the platelet count increased to 78 x 10(9)/L, and four days post-therapy, the platelet count was considered normal, at greater than 150 x 10(9)/L. Nine days post-therapy, the platelet count was greater than 250 x 10(9)/L.
In this clinical trial, patients with platelet levels greater than 150 x 10(9)/L measured on two separate occasions, at least one week apart, are classified as complete responders. The most recent platelet count remained greater than 150 x 10(9)/L, thus classifying this patient as a complete responder.
Cynthia Sullivan, president and CEO, said: "This initial result is very encouraging, but will need to be substantiated with more patients and monitoring for duration of response."
Source: Datamonitor
Related Articles
- Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
- GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
- Immunomedics Announces First Patient Dosing of Veltuzumab, Resulting in a Complete Response, in Immune Thrombocytopenic Purpura
- Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
- BioVascular, Inc. Merges With Revitus and Acquires First-In-Class Platelet Count Reducer
- Pivotal Phase III Trial Showed PROMACTA(R) (Eltrombopag Olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
- Updated Interim Long-Term Follow-Up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients With Immune Platelet Disorder
- Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
- Glaxo Drug Improves Platelet Count in Study
 |
 |
User Comments (0)
RSS Feeds